Mark A Glickman Insider Trading $ARLZ Old API Wind-down Ltd.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Mark A Glickman.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Mark A Glickman. Mark A Glickman is SVP, Sales & Marketing in OSCIENT PHARMACEUTICALS CORP ($GENE) and Chief Commercial Officer in POZEN INC /NC ($POZN) and Chief Commercial Officer in Esperion Therapeutics, Inc. ($ESPR) and Chief Commercial Officer in Aralez Pharmaceuticals Inc. ($ARLZ).
Mark A Glickman in Old API Wind-down Ltd.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Mark A Glickman: Chief Commercial Officer
Holdings: 250,188 shares
Current Value: $1,048,288
Latest Transaction: Mar 21 2018
$ARLZ Market Capitalization: $270.87M
$ARLZ Previous Close: $4.19
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Mark A Glickman in Old API Wind-down Ltd.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ESPR, ARLZ, GENE, POZN
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 21 2018 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Sell | S | 1.70 | 5,725 | 9,733 | 250,188 | 255.9 K to 250.2 K (-2.24 %) |
| May 12 2017 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Option Exercise | A | 1.56 | 92,621 | 144,489 | 92,621 | |
| May 12 2017 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Grant | A | 0.00 | 80,163 | 0 | 255,913 | 175.8 K to 255.9 K (+45.61 %) |
| Jun 24 2016 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Payment of Exercise | F | 3.34 | 10,803 | 36,082 | 175,750 | 186.6 K to 175.8 K (-5.79 %) |
| May 18 2016 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Buy | P | 3.68 | 25,000 | 92,050 | 186,553 | 161.6 K to 186.6 K (+15.47 %) |
| Mar 18 2016 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial of ... | Option Exercise | A | 3.80 | 38,559 | 146,524 | 38,559 | |
| Mar 18 2016 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial of ... | Grant | A | 0.00 | 45,553 | 0 | 161,553 | 116 K to 161.6 K (+39.27 %) |
| Feb 17 2016 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Grant | A | 0.00 | 86,863 | 0 | 116,000 | 29.1 K to 116 K (+298.12 %) |
| Feb 09 2016 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Buy | J | 0.00 | 29,137 | 0 | 29,137 | 0 to 29.1 K |
Page: 1